Kinnate Biopharma Inc. (KNTE) stands as a pioneering precision oncology company that is dedicated to developing selective small molecules that target genetic mutations and fusions. Their ultimate goal is to provide hope and inspiration to individuals fighting cancer by expanding the potential of targeted therapies. Through their expertise in structure-based drug discovery and translational research, they have created a robust pipeline of small molecule drug candidates that specifically target validated oncogenic drivers.
Let’s delve into some key details regarding Kinnate Biopharma Inc.’s common stock as of September 18, 2023:
– Ticker symbol: KNTE
– Exchange: U.S. Nasdaq
– 52-week range: $11.72 – $41.00
– Market cap: $548.82 million
– Shares outstanding: 43.7 million
– Public float: 18.28 million
– Beta: 1.49
– Short interest: 1.73 million shares (as of 12/31/21)
– % of float shorted: 9.47%
– Average volume: 100.99K shares
It is worth noting that the company’s stock price has experienced significant fluctuations. At one point, it endured a staggering 93% crash from its all-time high due to long overdue data from a Phase 1 study that failed to meet expectations. However, there has been a recent surge, with the stock gaining 27.04% over the past week. This positive trend has led to a bullish rating from the InvestorsObserver Sentiment Indicator.
Additionally, in terms of insider activity, two beneficial owners, FORESITE CAPITAL MANAGEMENT IV, LLC (with a 10% ownership) and TANANBAUM JAMES B. (a Director), have executed insider share trades on 05/08/2023.
Kinnate Biopharma Inc.
Updated on: 28/09/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
2:00 PM (UTC)
Date:27 September, 2023
|Analyst / firm||Rating|
KNTE Stock Performance: Mixed Results on September 18, 2023
KNTE stock experienced mixed performance on September 18, 2023. The stock opened at $1.73, slightly higher than the previous close of $1.70, but closed lower compared to the previous day’s close. Throughout the day, the stock price fluctuated within a range of $1.68 to $1.78. The trading volume for the day was 4,748 shares, significantly lower than the average volume of 315,741 shares over the past three months.
KNTE’s market capitalization stands at $80.1 million, indicating the company’s size in the market. However, the company has reported negative earnings growth in the past year, with a decline of 28.17%, and a decline of 14.30% in the current year. The lack of available data on revenue growth and price/sales ratio makes it difficult to assess the company’s overall financial performance. The P/E ratio is listed as NM, which stands for “not meaningful,” and the price/book ratio is 0.34, indicating that the stock is trading below its book value.
As of now, there are no competitors’ data available, making it challenging to compare KNTE’s performance within the industry. The next reporting date for the company is scheduled for November 9, 2023, which will provide further insight into its financial performance.
The EPS forecast for the current quarter is -$0.78, indicating an expected loss per share. In the previous year, the company reported zero annual revenue and a substantial annual loss of -$116.3 million. The net profit margin is not provided, making it difficult to evaluate the company’s profitability.
KNTE operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. However, there is no information available regarding the company’s executives or corporate headquarters.
Overall, KNTE’s stock performance on September 18, 2023, was mixed, with the stock opening higher but closing lower. The company has reported negative earnings growth in the past year and continues to experience declining earnings in the current year. With limited financial data available, it is challenging to assess the company’s overall financial health and profitability. Investors will need to monitor future financial reports and updates to gain a better understanding of KNTE’s performance and prospects.
Kinnate Biopharma Inc (KNTE) Stock Shows Promising Performances: Analysts Predict Potential Increase of +1,142.60%
On September 18, 2023, Kinnate Biopharma Inc (KNTE) showed promising stock performances based on the information provided by CNN Money. The company has garnered attention from six analysts who have offered their 12-month price forecasts for KNTE stock. The median target price is $21.00, with the highest estimate at $31.00 and the lowest estimate at $5.40. This indicates a potential increase of +1,142.60% from the last recorded price of $1.69.
The current consensus among seven polled investment analysts is to buy stock in Kinnate Biopharma Inc. This rating has remained steady since September, when it was unchanged from a buy rating. The positive sentiment from these analysts suggests confidence in the company’s future prospects and potential for growth.
In terms of the company’s financials, the current quarter’s earnings per share stand at -$0.78, indicating a loss. However, it is crucial to consider that earnings per share can fluctuate from quarter to quarter, and investors should evaluate the company’s overall financial health and performance over a longer period.
The sales for the current quarter are reported as $0.00, which may indicate that the company has not generated any revenue during this period. Investors should keep in mind that sales can vary from quarter to quarter, and it is essential to assess the company’s sales trends and growth potential over time.
Kinnate Biopharma Inc is expected to report its next earnings on November 9. Investors should pay attention to this reporting date as it can provide further insights into the company’s financial performance and potential impact on the stock’s value.
In conclusion, based on the information provided by CNN Money, Kinnate Biopharma Inc’s stock performances on September 18, 2023, showed promise. The median target price forecast by analysts suggests a significant potential increase from the last recorded price. The consensus among investment analysts to buy stock in the company further indicates positive sentiment. However, investors should conduct thorough research and analysis and consider the company’s financial health and performance over time before making any investment decisions.